Nasdaq First North-listed Qlucore, a leading software provider of visualization-based software for research-oriented data analysis and precision diagnostics, receives EUR 436k for participation in CARE-IN-HEALTH, a major EU project that will give people tools for improved health. The project will last five years and is the second recent project that the company has received a grant to participate in.

Cardiovascular diseases (CVD) are the world's leading cause of death and affect over 49 million people annually. The cost in healthcare and the pressure this puts on providers is high, EUR 90 billion per year for the EU alone, despite progress in the prevention and treatment of CVD.

To promote health, this EU project will develop and test tools for both healthcare providers and patients, so-called precision medicine. The solutions are aimed at remedying the chronic inflammation that leads to plaques in the arteries that in turn trigger the formation of blood clots. This is the main cause of heart attack and stroke.

”This project aims to improve the preventive treatment of patients at higher risk of cardiovascular disease by using precision medicine. The goal is to find early strategies to interrupt the inflammatory processes that lead to cardiovascular risk. This can provide significant benefits for society,” says Professor Magnus Bäck, project coordinator for CARE-IN-HEALTH.

”In addition to our ongoing work in cancer diagnostics, this is the second recent project in cardiovascular diseases that we have received funding for and it shows how relevant our solutions are. We will contribute with software and knowledge in machine learning to establish solutions so that a person’s risk of being affected can be reduced” says Carl-Johan Ivarsson, CEO of Qlucore.

The project will involve ten participants, the two Swedish participants are from Karolinska Institutet and Qlucore. The project coordinator is Magnus Bäck of INSERM in France.